ANI Pharmaceuticals IncANIP
Price$72.65Intrinsic value$129.3778% above price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $129.37median of 6 methods · middle span $105-$361based on filings through 30 Jun 2026
Market Price $72.65Price as of 30 Sep 2026
Margin of Safety +78.1%as of 30 Sep 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 17.1% (near-term consensus, capped) · years 2–5: 14.2%/yr (balance of the path).14.8% per year
Years 6–10: glide to demonstrated growth own history 27.6%, capped at 20%
Per-year rates
Yr 614.4%Yr 714.5%Yr 814.6%Yr 914.7%Yr 1014.8%
14.2% → 14.8%
Years 11–20: glide to long-run rate
Per-year rates
Yr 1113.6%Yr 1212.4%Yr 1311.3%Yr 1410.1%Yr 158.9%Yr 167.7%Yr 176.5%Yr 185.4%Yr 194.2%Yr 203.0%
14.8% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 2 windows (6/7y) (limited history)27.6%
Discount rate (cost of equity) 7.8%
Volatility vs market (adjusted beta)0.64

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetANI Pharmaceuticals IncANIPHealth Care
Valuation
P/E15.8×
P/S1.8×
P/B2.9×
EV / Revenue1.7×
EV / EBITDA10.3×
Profitability
Gross margin60.6%
Operating margin16.4%
Net margin11.1%
FCF margin17.7%
Returns
ROE18.1%
ROA7.2%
ROIC20.1%
Growth
Revenue growth (YoY)59.2%
5-yr fwd EPS growth14.8%
Financial strength
Debt / Equity0.50×
Current ratio2.91×
Altman Z-Score2.7
Interest coverage—
Dividend yield—

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.